The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Case Report

Gemcitabine Plus Vinorelbine as an Effective Salvage Chemotherapeutic Regimen in Cisplatin-Refractory Germ Cell Tumor

Authors: Jia-Hong Chen MD, Ping-Ying Chang MD, Nai-Shun Yao MD

Abstract

Abstract:Germ cell tumors (GCT) are the most common malignancies among male adolescents. Approximately 5% of GCTs are of extragonadal origin. Cisplatin-based chemotherapy is the standard first-line treatment for GCT. Patients who fail to respond to first-line treatment usually have poor outcomes. High-dose chemotherapy with stem cell support, paclitaxel, gemcitabine, and oxaliplatin are reported as effective salvage treatment. We report two patients with cisplatin-refractory, metastatic, nonseminomatous, and extragonadal GCT treated successfully with gemcitabine plus vinorelbine (GV). One patient achieved good partial remission and had a five-month progression-free period. Another patient is still alive with stable disease after 4 cycles of treatment. In heavily treated, cisplatin-refractory GCT patients, GV could be considered an effective chemotherapeutic regimen.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Schmoll HJ. Extragonadal germ cell tumors. Ann Oncol 2002;13(suppl 4):265–272.SchmollHJExtragonadal germ cell tumors.Ann Oncol200213265-2722. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumor. Cancer 2006;106:1217–1226.KollmannsbergerC]]NicholsC]]BokemeyerCRecent advances in management of patients with platinum-refractory testicular germ cell tumor.Cancer20061061217-12263. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357:340–348.EinhornLH]]WilliamsSD]]ChamnessA&etal;High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.N Engl J Med2007357340-3484. Chen YM, Perng RP, Yang KY, et al. A multicenter phase II trial of vinorelbine plus Gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000;117:1583–1589.ChenYM]]PerngRP]]YangKY&etal;A multicenter phase II trial of vinorelbine plus Gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer.Chest20001171583-15895. Martín M, Ruiz A, Muñoz M, et al; Spanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219–225.MartínM]]RuizA]]MuñozM&etal;Spanish Breast Cancer Research Group (GEICAM) trialGemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.Lancet Oncol20078219-2256. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493–497.PectasidesD]]PectasidesM]]FarmakisD&etal;Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.Ann Oncol200415493-497